AGIO — Agios Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $1.69bn
- $793.66m
- $36.50m
- 34
- 68
- 72
- 60
Annual income statement for Agios Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 14.2 | 26.8 | 36.5 |
| Cost of Revenue | |||||
| Gross Profit | — | — | 12.5 | 23.9 | 32.3 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 336 | 372 | 266 | 418 | -627 |
| Operating Profit | -336 | -372 | -251 | -391 | 663 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -329 | -357 | -232 | -352 | 718 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -329 | -357 | -232 | -352 | 674 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -327 | 1,605 | -232 | -352 | 674 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -327 | 1,605 | -232 | -352 | 674 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -4.77 | -6.01 | -6.74 | -6.33 | -0.591 |